QualityStocksNewsBreaks Archives - Page 852 of 1515

TuesdayFeb 23, 2021 9:13 am

QualityStocksNewsBreaks – Augusta Gold Corp. (OTCQB: AUGG) (CSE: G) (FSE: 11B) Announces It Will Grant Stock Options

Augusta Gold (OTCQB: AUGG) (CSE: G) (FSE: 11B), a rapidly growing exploration and development company focused on building a long-term business that delivers stakeholder value, has granted stock options to key individuals associated with the company. Augusta announced the grant of 5.8 million stock options to company officers, directors and employees, based on guidelines of the company’s stock option plan. The stock options have an exercise price of C$3 per share with an expiration date of five years following the date of the grant. In addition, Augusts also announced that, following its recent name change, the company has also changed its OTCQB trading…

MondayFeb 22, 2021 3:05 pm

QualityStocksNewsBreaks – Brain Scientific Inc.’s (BRSF) E-Tattoo Will Be ‘Next Wave of Innovation for Neurology’

Brain Scientific (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. As scientists work to understand what causes Parkinson’s, Alzheimer’s, dementia and other neurological issues, BRSF is making inroads in helping identify root neurological problems. The company has unveiled a new initiative to develop an innovative e-tattoo device for the brain diagnostics market. The Brain E-Tattoo’s graphene-based electrodes are designed for connection to the micro EEG clipped behind the ear, which processes the signals from the sensors and wirelessly transfers data to a cloud application. The solution enables each patient’s data…

MondayFeb 22, 2021 2:55 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Eyes Transformation as Berubicin Becomes Subject of Active Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. The company’s pipeline includes Berubicin for the treatment of patients with glioblastoma multiforme (“GBM”), an aggressive form of brain cancer that is incurable. CNS is currently focused on the development and clinical trials of Berubicin for GBM, as well as the potential of addressing other central nervous system malignancies. “The company will transform within the next several months as Berubicin becomes the subject of up to three active clinical trials, which include our…

MondayFeb 22, 2021 2:34 pm

QualityStocksNewsBreaks – Hollywall Entertainment Inc.’s (HWAL) HW Vision to Advance Technological Footprint Through Strategic Agreement

Hollywall Entertainment (OTC: HWAL), an innovative telecommunication and broadcasting company, has begun the rollout of its new wholly owned subsidiary HW Vision. According to a recent update, the subsidiary will provide branded cellular equipment and services, streaming media content, live television and on-demand programming as part of Hollywall’s drive to become a major media and entertainment conglomerate. An article discussing this reads, “HWAL’s subsidiary HW Vision will be advancing its technological footprint via its entry into an agreement to acquire top United States telecommunications firm Omnipoint Technology Inc., a Massachusetts-based telecommunications company, to deliver the services — including content from…

MondayFeb 22, 2021 12:43 pm

QualityStocksNewsBreaks – Pac Roots Cannabis Corp. (CSE: PACR) (OTCQB: PACRF) Marks Major Milestone Through Lords of Grasstown Acquisition

Pac Roots (CSE: PACR) (OTCQB: PACRF) (“PacRoots”) today announced the closing of a share purchase agreement with the shareholders of Lords of Grasstown Holdings Ltd., a company existing under the laws of British Columbia (“Grasstown”). Under the agreement, the company will acquire all issued and outstanding shares of Grasstown, a well-established cannabis motorcycle lifestyle brand with a tremendous following and acumen that spawned from the vision of Tyler Hazelwood, founder and director of Lords of Gastown. “This acquisition marks a major milestone for the company with a move into the U.S. Cannabis Market, predominantly in California, with the Grasstown Brand,”…

MondayFeb 22, 2021 11:31 am

QualityStocksNewsBreaks – Amesite (NASDAQ: AMST) Founder, CEO Slated to Present at Upcoming Diamond Equity Research Emerging Growth Conference

Amesite (NASDAQ: AMST) founder and CEO Dr. Ann Marie Sastry is scheduled to present at the Diamond Equity Research Emerging Growth Invitational. The one-day premier event will be held on Wednesday, Feb. 24, with Sastry’s presentation scheduled for 12:20 p.m. ET. During her presentation, Sastry will provide an overview of the Amesite story and discuss how the company’s award-winning, highly scalable artificial intelligence (“AI”) driven platform is impacting the way the world learns. A live audio webcast and archive of the conference presentation will be available using the registration link. AMST operates in a U.S. online learning market of $350 billion and is becoming…

MondayFeb 22, 2021 10:47 am

QualityStocksNewsBreaks – Grapefruit USA Inc. (GPFT) Obtains California Trademark Protection for Flagship Hourglass Cream

Grapefruit USA (OTCQB:GPFT), a premiere, fully licensed California-based cannabis company, announced that it has secured trademark protection for its Hourglass name and logo. The now-protected name and logo are used on Grapefruit’s patented disruptive Hourglass(TM) THC/cannabinoid time-release delivery cream. With the approved trademark, the Hourglass name and logo are now categorized as protected intellectual property rights of Grapefruit USA Inc. That status means that no other company operating in the cannabis space can use the property; the announcement noted that Grapefruit also possesses common-law, first-in-time, trademark protection to Hourglass. In addition, the company has secured California trademark and service mark…

MondayFeb 22, 2021 10:45 am

QualityStocksNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by Encode Ideas L.P., a health care focused research firm. The full research publication is available at https://ibn.fm/NqQs7. The report reads, “Processa’s pipeline is constructed of development-stage assets that have substantial legacy human data, where the company believes a new approach (dosing, indication, trial design, etc.) can unlock latent value. Processa’s management (David Young, Questcor) and board (Khalid Islam, Gentium and Fennec) have a history of successful drug reclamation…

MondayFeb 22, 2021 10:13 am

QualityStocksNewsBreaks – Clean Power Capital Corp.’s (CSE: MOVE) (OTC: MOTNF) (FWB: 2K6A) PowerTap to Commercialize 3rd Generation Blue Hydrogen System into New Verticals

Clean Power (CSE: MOVE) (OTC: MOTNF) (FWB: 2K6A) today provided additional information about how the onsite hydrogen production and dispensing technology being developed by PowerTap Hydrogen Fueling Corp., an investee company of Clean Power, will be used in other commercial markers. According to the update, PowerTap has commenced plans to commercialize its third generation units into new verticals such as commercial buses and trains, and has initiated partnership discussions with various cities and states/provinces. Subject to the progression of PowerTap’s plan to expand its product offering, its third generation onsite hydrogen production module will be made available to provide blue…

MondayFeb 22, 2021 10:09 am

QualityStocksNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Expedited Formation of Team to Launch Test System, Also Comments on Lawsuit Against German Subsidiary

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) announced that it has accelerated the creation of a commercial team formed to launch its point-of-care COVID-19 RT-PCR (“RT-PCR”) test system, called the COVID ID Lab. The lab was developed by XPhyto's exclusive German diagnostics development partner, 3a-diagnostics GmbH ("3a"). It is anticipated that 3a will receive ISO 13485 medical device manufacturer approval by the end of February; European regulatory approval should be received by early March. The announcement noted that the market launch team consists of highly skilled clinical and pharmaceutical executives and service providers with the expertise and background to rapidly…

Site Search

Company Search

Category: QualityStocksNewsBreaks